Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Portfolio Pulse from
Basilea Pharmaceutica Ltd has entered into an exclusive agreement with Innoviva Specialty Therapeutics for the commercialization of its antibiotic Zevtera® in the US.
December 16, 2024 | 6:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innoviva Inc. has secured an exclusive distribution and license agreement for the commercialization of Basilea's antibiotic Zevtera® in the US.
The agreement allows Innoviva to expand its product offerings in the US market with a new antibiotic, potentially increasing its revenue and market presence.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80